Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance

FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us

An incredible moment of pause #HFSA2019 - honoring Doug Mann, Lifetime Achievement Award. An exemplar as a scientist; inspiration as a mentor; & a pillar of humanism, integrity and character. A privilege to know him as a friend. Humble congrats; deep respect. #mensch

Incredible honor to have Dr. Kricket Seidman as the winner of Vanderbilt Prize in Research! A true pioneer in cardiology! @VUMChealth @jct_ucb @bwhcvls @BWHGenetics @harvardmed @HHMINEWS @VUMCResearch @VUMC_MedPSTP @VUMChealth @VUMCgenetics @DLBHATTMD @sday_hcm

we are putting in an NIH grant to look at long term effects of ICI on cardiac and vascular health. Pre-clinical data from Andy Lichtman @harvardmed on development of athero in PD-1-/- mice over time. Chance to collaborate? @onco_cardiology

Completely agree w/ lack of follow-up @bradloncar Also hope he touched on the toxicities w/ combination ICI Rx. Challenge clinically. As a cardiologist, worry about acute issue (e.g., myoacarditis) as well as long-terms effects (?vascular tox/atherosclerosis). @onco_cardiology